GlassScriptPhysician profile
Bridget Peery
NPI 1619322930
$1,682.41
in general payments reported to CMS, 2019-2025
14 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $563 · 2022: $794 · 2023: $203 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.56 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $313.65 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $164.09 | 2021-2023 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $148.26 | 2021-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $96.65 | 2021-2023 | Spravato |
| Corium, LLC | $87.51 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $85.84 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $78.18 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $75.73 | 2022-2023 | Gralise |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.58 | 2022-2023 | |
| Lundbeck LLC | $65.49 | 2021-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $46.70 | 2022-2023 | Austedo |
| Supernus Pharmaceuticals, INC. | $31.16 | 2021 | |
| Axsome Therapeutics, INC. | $22.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Peery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.